Concepedia

Publication | Open Access

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

DOIFull Paper Access

22

Citations

16

References

2014

Year

Hyun Jung Lee, Dae Seog Heo, Joo‐Youn Cho, Sae‐Won Han, Hye-Jung Chang, Hyeon‐Gyu Yi, Tae‐Eun Kim, Se‐Hoon Lee, Do‐Youn Oh, Seock‐Ah Im,
Cancer Research and Treatment

Abstract

The study drug appears to be well tolerated, and the effective plasma concentration of paclitaxel was achieved. The recommended phase II dose for oral paclitaxel is 300 mg/m(2).

References

YearCitations

Page 1